載入...
A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment
BACKGROUND AND OBJECTIVES: In 10% to 20% of cases, Kawasaki disease is refractory to intravenous immunoglobulin (IVIg), an expensive medication under a national shortage. Data suggest that infliximab is a viable alternative to a second dose of IVIg, with similar efficacy and safety. We compared the...
Na minha lista:
| 發表在: | Hosp Pediatr |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Academy of Pediatrics
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7769204/ https://ncbi.nlm.nih.gov/pubmed/33293266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1542/hpeds.2020-0188 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|